Agalsidase beta slows the progression of renal outcomes in Fabry disease patients: A systematic literature review

被引：0
|
作者：
Fan, Qi [1 ]
Wilson, Florence [2 ]
DasMahapatra, Pronabesh [1 ]
Maski, Manish [1 ]
Hariri, Ali [1 ]
Adeyemi, Adekemi [2 ]
Wu, Ping [2 ]
Hamed, Alaa [1 ]
机构：
[1] Sanofi Genzyme, Cambridge, MA USA
[2] Precis Xtract, Vancouver, BC, Canada
来源：
MOLECULAR GENETICS AND METABOLISM | 2020年 / 129卷 / 02期
关键词：
D O I：
10.1016/j.ymgme.2019.11.124
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
115
引用
收藏
页码：S55 / S55
页数：1
相关论文
共 50 条
  • [41] Clinical outcomes in patients switching from agalsidase beta to migalastat: A Fabry Registry analysis
    Pisani, Antonio
    Wilson, Kathryn
    Batista, Julie
    Kantola, Ilkka
    Arduan, Alberto Ortiz
    Politei, Juan
    Al-Shaar, Laila
    Maski, Manish
    Crespo, Ana
    Ponce, Elvira
    Linhart, Ales
    MOLECULAR GENETICS AND METABOLISM, 2024, 141 (02)
  • [42] SWITCH FROM AGALSIDASE BETA TO AGALSIDASE ALFA IN THE ENZYME REPLACEMENT THERAPY OF PATIENTS WITH FABRY DISEASE IN LATIN AMERICA
    Ripeau, Diego
    Amartino, Hernan
    Cedrolla, Martin
    Urtiaga, Luis
    Urdaneta, Bella
    Cano, Marilis
    Valdez, Rita
    Antongiovanni, Norberto
    Masllorens, Francisca
    MEDICINA-BUENOS AIRES, 2017, 77 (03) : 173 - 179
  • [43] Antibody measurement on switching from agalsidase alfa to agalsidase beta in the treatment of Fabry disease
    Peters, C.
    Burling, K.
    Deegan, P. B.
    ACTA PAEDIATRICA, 2008, 97 : 111 - 112
  • [44] Agalsidase alfa and agalsidase beta in the treatment of Fabry disease: does the dose really matter?
    Pisani, Antonio
    Riccio, Eleonora
    Sabbatini, Massimo
    GENETICS IN MEDICINE, 2015, 17 (01) : 21 - 23
  • [45] Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: an international cohort study
    Arends, Maarten
    Biegstraaten, Marieke
    Wanner, Christoph
    Sirrs, Sandra
    Mehta, Atul
    Elliott, Perry M.
    Oder, Daniel
    Watkinson, Oliver T.
    Bichet, Daniel G.
    Khan, Aneal
    Iwanochko, Mark
    Vaz, Frederic M.
    van Kuilenburg, Andre B. P.
    West, Michael L.
    Hughes, Derralynn A.
    Hollak, Carla E. M.
    JOURNAL OF MEDICAL GENETICS, 2018, 55 (05) : 351 - 358
  • [46] LONG-TERM OUTCOME OF AGALSIDASE BETA THERAPY IN 10 ADULT MALE PATIENTS WITH FABRY DISEASE AND RENAL ALLOGRAFT
    Tran, T. -C.
    Benistan, K.
    Froissart, M.
    Germain, D. P.
    CLINICAL THERAPEUTICS, 2009, 31 : S39 - S40
  • [47] Safety and pharmacokinetics of agalsidase alfa in patients with Fabry disease and end-stage renal disease
    Pastores, Gregory M.
    Boyd, Ellen
    Crandall, Kerry
    Whelan, Alison
    Piersall, Linda
    Barnett, Natalie
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2007, 22 (07) : 1920 - 1925
  • [48] Agalsidase therapy in patients with Fabry disease on renal replacement therapy: a nationwide study in Italy
    Mignani, Renzo
    Feriozzi, Sandro
    Pisani, Antonio
    Cioni, Antonio
    Comotti, Cristina
    Cossu, Maria
    Foschi, Annalisa
    Giudicissi, Antonio
    Gotti, Eliana
    Lozupone, Vito Antonio
    Marchini, Francesco
    Martinelli, Fabrizio
    Bianco, Francesco
    Panichi, Vincenzo
    Procaccini, Deni Aldo
    Ragazzoni, Elena
    Serra, Andrea
    Soliani, Fausto
    Spinelli, Letizia
    Torti, Giacomo
    Veroux, Massimiliano
    Cianciaruso, Bruno
    Cagnoli, Leonardo
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2008, 23 (05) : 1628 - 1635
  • [49] Evaluation of glycosphingolipid clearance in patients with Fabry disease treated with agalsidase alfa who switched to agalsidase beta (the INFORM study)
    Barranger, John A.
    Gambello, Michael J.
    Goker-Alpan, Ozlem
    Maegawa, Gustavo H. B.
    Nedd, Khan J.
    Gruskin, Daniel J.
    Blankstein, Larry
    Weinreb, Neal J.
    MOLECULAR GENETICS AND METABOLISM, 2014, 111 (02) : S24 - S24
  • [50] Clinical development of agalsidase-beta for the treatment of Fabry disease
    Germain, DP
    M S-MEDECINE SCIENCES, 2005, 21 : 57 - 61
12345